文献速递肿瘤 PET/CT

18F-DOPA PET/CT与68Ga-DOTANOC PET/CT在中肠神经内分泌肿瘤中的头对头比较

Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors.
PubMed 文献 · Clin Nucl Med · 2021-01-01

结果显示18F-DOPA PET/CT在检测受累区域和转移病灶方面显著优于68Ga-DOTANOC PET/CT,灵敏度分别为95.5%和88.2%(P < 0.0001),且18F-DOPA的肝脏肿瘤/本底比值更有利。

要点

  • 18F-DOPA PET/CT检测病灶灵敏度95.5%,显著高于68Ga-DOTANOC的88.2%(P < 0.0001)。
  • 18F-DOPA PET/CT在更多患者中检出更多受累区域和转移病灶。
  • 18F-DOPA的肝脏肿瘤/本底比值优于68Ga-DOTANOC。

核心结论

  • 18F-DOPA PET/CT在病灶检测方面优于68Ga-DOTANOC PET/CT,可推荐作为中肠NET准确分期的一线检查。

主要发现

  • 18F-DOPA PET/CT在6例(20%)患者中检出更多受累区域,在10例(33.3%)患者中检出更多转移病灶。
  • 81个确认受累区域中,18F-DOPA PET/CT检出77个(95%),68Ga-DOTANOC检出71个(87.7%)(P < 0.0001)。
  • 18F-DOPA PET/CT检出211/221个病灶,68Ga-DOTANOC检出195/221个,灵敏度分别为95.5%和88.2%(P < 0.0001)。
  • 18F-DOPA的肝脏肿瘤/本底比值优于68Ga-DOTANOC;18F-DOPA SUVmax与肿瘤负荷尤其是受累区域数量相关(P = 0.019)。

临床怎么用

  • 在可获取18F-DOPA的条件下,可将其作为中肠NET准确分期的一线PET/CT显像剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to compare retrospectively 18F-DOPA PET/CT versus 68Ga-DOTANOC PET/CT in a group of patients affected by midgut NET. PATIENTS AND METHODS: Patients with histologically proven grade 1 or grade 2 midgut NET were explored after injection of 150 MBq of 68Ga-DOTANOC and 210 MBq of 18F-DOPA. The PET/CTs were analyzed visually and semiquantitatively at the patient level, regional level (7 defined regions), and lesion level (maximum of 5 lesions/organ). The criterion standard was determined on the basis of histology and imaging follow-up. RESULTS: Thirty patients (17 males and 13 females; median age, 63.5 years [37-82 years]) were included. Both PET/CTs were negative in 3 patients and positive in 25 patients. PET/CTs were discordant in 2 patients, with 18F-DOPA positive and 68Ga-DOTANOC negative. 18F-DOPA PET/CT detected more involved regions and more metastatic lesions than 68Ga-DOTANOC PET/CT in 6 (20%) and 10 (33.3%) patients, respectively. Of the 81 confirmed affected regions, 77 (95%) were detected by 18F-DOPA PET/CT and 71 (87.7%) by 68Ga-DOTANOC PET/CT (P < 0.0001). 18F-DOPA PET/CT detected significantly more lesions (211/221) than 68Ga-DOTANOC PET/CT (195/221), corresponding to a sensitivity of 95.5% and 88.2%, respectively (P < 0.0001). Tumor-to-background ratios were more favorable in liver for 18F-DOPA than for 68Ga-DOTANOC. Interestingly, a correlation was found between 18F-DOPA SUVmax and tumor burden and especially with the number of regions involved by the disease (P = 0.019). CONCLUSIONS: 18F-DOPA PET/CT is superior to 68Ga-DOTANOC PET/CT for the detection of lesions, and when available, this tracer may be recommended as the first-line examination for an accurate staging of midgut NET.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ansquer C, Touchefeu Y, Faivre-Chauvet A, et al. Head-to-Head Comparison of 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT in Patients With Midgut Neuroendocrine Tumors. Clin Nucl Med. 2021. PMID: 33315677. doi:10.1097/RLU.0000000000003450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。